PharmTech Drug Digest 11.20
News|Articles|June 9, 2015

Patheon Files Registration For IPO

A year after its merger with DSM Pharmaceutical Products, Patheon announces that it has filed an IPO.

 

Patheon announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission (SEC) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined, the company reports in a statement.

J.P. Morgan, Morgan Stanley, Jefferies and UBS will act as joint book-running managers for the proposed offering.

In March 2014, Patheon completed its $2.65 billion merger with DSM Pharmaceutical Products (DPP) to form DPx.

In April 2015, Patheon completed the acquisition of IRIX Pharmaceuticals, a Florence, SC company that specializes in API development and manufacturing. This follows the March 2015 acquisition of Agere Pharmaceuticals, Inc., a privately-held CDMO, that specializes in improving drug bioavailability.

Source: Patheon


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.